Developer docs
API playgroundTry for free, no card

Search company profiles

ARTMS

Full company profile

uuid0003agh

Namestring
ARTMS
Legal namestring
ARTMS Inc.
Websiteurl
artms.ca
Company typeenum
Private
Founded yearint
2013
Descriptiontext

ARTMS Inc. (Alternative Radioisotope Technologies for Medical Science) is a Canadian medical technology company that develops the QUANTM Irradiation System (QIS) and a portfolio of proprietary solid targets to enable decentralized, cyclotron-based production of medical radioisotopes. Founded in 2013 by TRIUMF scientists to address projected technetium-99m supply disruptions, ARTMS targets hospital-based medical cyclotron operators, commercial nuclear pharmacies, and radiopharmaceutical manufacturers across North America, Europe, and select Asia-Pacific and Latin America markets. Following its April 2024 acquisition by Telix Pharmaceuticals Limited (ASX: TLX), ARTMS operates as Telix ARTMS, Inc. and functions as the manufacturing and supply-chain backbone for Telix's cyclotron-produced isotope strategy.

The QUANTM platform comprises three integrated components: an automatic 2-way pneumatic transfer system, a compact solid target station, and single-use enriched metal targets (QUANTM-68 Zn-68 for Ga-68, QUANTM-99 Mo-100 for Tc-99m, QUANTM-89 Y-89 for Zr-89, QUANTM-64 Ni-64 for Cu-64). Production volumes significantly exceed conventional generators — 5,000 mCi Ga-68 per 2-hour run, up to 37-40 Ci Tc-99m per 6-hour run, over 50 mCi/hour Zr-89, and over 200 mCi/hour Cu-64 — while avoiding enriched uranium and long-lived radioactive waste. The QIS is compatible with most OEM medical cyclotron platforms and is retrofittable to installed units with minimal operational disruption.

ARTMS operates a hybrid revenue model: one-time QIS hardware sales and installation services combined with recurring consumable target revenue (single-use targets plus proprietary Ni-64 recycling), augmented by regulatory licensing where radiopharmaceutical innovators reference ARTMS's FDA Drug Master Files and Health Canada Type 1 Master Files in their drug applications — most notably Telix's Gozellix (Ga-68 gozetotide), approved by FDA in 2025. Distribution combines direct enterprise sales with an OEM-embedded channel through GE Healthcare's PETtrace 800 series. ARTMS holds global patent rights for cyclotron Tc-99m production, has achieved Health Canada approval, CE marking, and FDA DMF filings, and is ISO 9001 certified.

Short descriptiontext

ARTMS (now Telix ARTMS) develops the QUANTM Irradiation System and solid targets that enable decentralized cyclotron-based production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64), serving hospital cyclotron operators, radiopharmacies, and radiopharmaceutical manufacturers globally.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurnaby, Canada
HQ citystring
Burnaby
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cyclotron isotope production, medical radioisotope manufacturing, solid target irradiation, radiopharmaceutical supply, diagnostic imaging isotopes
Industry3 codes
PRIMARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Isotope Production Equipment
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1QUANTM Irradiation System (QIS) Hardware Sales
TypeHardware Sales
Description

Sale of QIS hardware systems (pneumatic transfer, target station, processing equipment) to cyclotron operators including hospitals, radiopharmacies, and pharmaceutical distributors. Installation and commissioning services included. System is retrofittable to existing cyclotrons with minimal disruption.

artms.ca
2QUANTM Solid Target Consumables
TypeHardware Sales
Description

Recurring sale of proprietary solid target consumables (Mo-100, Zn-68, Y-89, Ni-64 targets) to cyclotron operators. Targets are single-use. ARTMS also provides proprietary recycling of Ni-64 targets for reuse, ensuring supply chain continuity.

artms.ca
3Regulatory/DMF Filing Services
TypeLicensing Royalties
Description

ARTMS prepares and files Drug Master Files (DMF) with regulatory bodies (FDA, Health Canada) for cyclotron-produced isotopes, enabling pharmaceutical companies to reference these in their drug applications. This creates a service/embedded relationship with radiopharmaceutical innovators.

4Technology Integration and Licensing to OEM Partners
TypeLicensing Royalties
Description

Licensing of QIS technology to OEM cyclotron manufacturers (e.g., GE Healthcare) for integration into their platforms. Revenue from equipment manufacturers embedding ARTMS technology in cyclotron offerings.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1QUANTM Irradiation System (QIS™)
Description

Complete cyclotron-based isotope production system designed to support high efficiency, large-scale and cost-effective production of medical isotopes including Zr-89, Ga-68, Tc-99m, and Cu-64.

artms.ca
+4 more records
Core offering1 text field

ARTMS develops and sells the QUANTM Irradiation System (QIS), a cyclotron-based hardware platform consisting of automatic pneumatic transfer, a compact solid target station, and processing solutions for decentralized production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64). The company also produces and supplies proprietary single-use solid targets (QUANTM-68, QUANTM-99, QUANTM-89, QUANTM-64) that pair with the QIS on hospital-based medical cyclotrons. It files Drug Master Files (DMFs) with regulators that radiopharmaceutical innovators reference in their drug applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 99mTc is used in over 50 million diagnostic studies annually worldwide
+5 more records
Product overview1 text field

ARTMS offers the QUANTM Irradiation System (QIS) as its core platform for decentralized medical isotope production, paired with a portfolio of specialized solid targets (QUANTM-68, QUANTM-99, QUANTM-89, QUANTM-64) for producing Gallium-68, Technetium-99m, Zirconium-89, and Copper-64 respectively. The QIS enables hospitals and radiopharmacies with medical cyclotrons to produce these critical diagnostic isotopes locally, eliminating dependence on centralized reactor-based supply. The system integrates with OEM cyclotron platforms and includes automated target processing and purification capabilities.

Product and service5 records
1QUANTM Irradiation System (QIS)
CategoryMedical Isotope Production Equipment
Description

Complete cyclotron-based isotope production system consisting of automatic 2-way pneumatic transfer, a compact solid target station, and complete solid target processing solutions. Enables decentralized, large-scale, cost-effective production of medical isotopes on hospital-based medical cyclotrons and commercial nuclear pharmacies.

2QUANTM-68 (Gallium-68) Solid Target
CategorySolid Target Consumables
Description

Single-use Zinc-68 target with silver backing for cyclotron production of Gallium-68. Provides up to 5,000 mCi of Ga-68 per two-hour cyclotron irradiation at optimal energy of 12.7 MeV; dissolution and purification in 40 minutes. Used for PET imaging of neuroendocrine tumors and prostate cancer.

3QUANTM-99 (Technetium-99m) Solid Target
CategorySolid Target Consumables
Description

Single-use Molybdenum-100 target with copper or tantalum backing for cyclotron production of Technetium-99m. Yields up to 37-40 Ci at optimal 24 MeV and 500 uA over a 6-hour irradiation; dissolution and purification in approximately 2 hours. Approved by Health Canada for clinical use.

4QUANTM-89 (Zirconium-89) Solid Target
CategorySolid Target Consumables
Description

Single-use Yttrium-89 target with tantalum backing for cyclotron production of Zirconium-89. Yields over 50 mCi per hour at optimal 13 MeV; irradiations can exceed 12 hours; dissolution and purification under 1.5 hours. Used for Immuno-PET imaging in oncology.

5QUANTM-64 (Copper-64) Solid Target
CategorySolid Target Consumables
Description

Nickel-64 target with rhodium backing and range of Ni-64 mass for cyclotron production of Copper-64. Yields over 200 mCi per one-hour irradiation at optimal energy under 13 MeV; dissolution and purification under 2 hours. Includes proprietary Ni-64 recycling solution for stable supply. Used for oncology PET applications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-14
Description

Tri-party co-operation with POINT Biopharma and CanProbe for the development and clinical use of innovative Ga-68-based radiopharmaceuticals in Canada. ARTMS' solid target approach enables 100-fold increase in Ga-68 availability over generator supply. POINT aims to use this supply for next-generation radiopharmaceutical therapies.

2CanProbe (Centre for Probe Development and Commercialization and University Health Network)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-14
Description

Tri-party co-operation with CanProbe (joint venture between CPDC and UHN) and POINT Biopharma for Ga-68 radiopharmaceutical development in Canada. CanProbe enables 100-fold increase in Ga-68 availability using ARTMS QIS compared to generator supply, working with innovators to meet patient needs.

artms.ca
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-19
Description

Successful multi-curie radiolabeling of Isotopia's PSMA-11 prostate cancer imaging kit with over 2 Ci of cyclotron-produced Ga-68 using ARTMS QIS. Demonstrated 6-hour stability and radiochemical purity meeting regulatory standards. Enables near unlimited access to diagnostic product for radiopharmacies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-19
Description

Founding technology collaboration institutions. ARTMS' core technology stems from TRIUMF (Canada's particle accelerator centre), BC Cancer, CPDC, and Lawson Health Research. Early stage research funded by NSERC and the Isotope Technology Acceleration Program (ITAP). These institutions participated in Canadian consortium for Health Canada submission.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-06
Description

Manufacturing collaboration for high-activity Ga-68 production using ARTMS QIS for Telix's prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11). ARTMS provides cyclotron technology and Zn-68 target irradiations; Telix provides radiochemistry expertise. Collaboration used in marketing authorization applications. ARTMS subsequently acquired by Telix in April 2024.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Strategic partnership to explore novel radiochemistry manufacture of ImaginAb's lead asset 89Zr CD8 immunoPET agent. ARTMS' QIS platform produces Zr-89 for labeling of molecular targeting ligands such as antibodies for Immuno-PET imaging.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-10-10
Description

Collaboration with scientists and clinical researchers from Odense University Hospital and University of Southern Denmark. Demonstrated record Ga-68 production levels from a single short-duration irradiation of QUANTM 68Zn Target Plates. Data presented at European Association of Nuclear Medicine conference.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-08-29
Description

Strategic partnership for ARTMS' QUANTM99 Irradiation System (QIS) integrated with GE's PETtrace 800 series medical cyclotron platform. Includes agreement for first European QIS installation and joint research into expanding isotope production (Cu-64, Ga-68). ARTMS supplies equipment, technologies, and research; GE Healthcare provides platform access and distribution.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-05-15
Description

Strategic partnership to demonstrate and gain regulatory marketing approval for alternative non-reactor Tc-99m supply within the United Kingdom. ARTMS provides hardware, know-how, and proprietary consumables to enable and demonstrate cyclotron-produced Tc-99m. Reduces UK reliance on foreign reactor-based production and enriched uranium.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

IBA is a major manufacturer of medical cyclotrons (similar to GE Healthcare's PETtrace), providing both the cyclotron hardware and increasingly integrated targetry and processing solutions. IBA competes directly with ARTMS on integrated isotope production platforms.

TypeBroad incumbent
Description

Lantheus is a major radiopharmaceutical company with established diagnostic imaging products (e.g., PYLARIFY PSMA-PET, Definity). Both companies serve the same end customers in nuclear medicine; ARTMS provides upstream isotope production infrastructure while Lantheus provides finished imaging agents.

TypeBroad incumbent
Description

Telix is ARTMS's parent company post-April 2024 acquisition. As both a strategic acquirer/parent and a leading radiopharmaceutical innovator (Gozellix, Illuccix), Telix represents the vertical integration of ARTMS's isotope supply into commercial drug products.

TypeBroad incumbent
Description

Curium is one of the largest global manufacturers of diagnostic radiopharmaceuticals and SPECT/PET tracers. As both a potential customer of ARTMS isotope production technology and a competitor in the broader radiopharma supply chain, Curium is a critical industry peer.

TypeRegional player
Description

Cardinal Health operates one of the largest US nuclear pharmacy networks, distributing radiopharmaceuticals to hospitals and clinics. It is a primary US distribution channel for SPECT/PET tracers and a potential large-scale customer of ARTMS QIS installations.

TypeEmerging player
Description

ITM is a specialized radiotherapeutics company developing Lu-177 and other therapeutic isotopes, with manufacturing capabilities including cyclotron-based production. It overlaps with ARTMS in isotope production technology for emerging therapeutic applications including potential Ac-225 supply.

TypeDirect peer
Description

NorthStar is the most direct competitor to ARTMS in non-reactor Mo-99/Tc-99m production, using electron accelerators rather than cyclotrons. Both companies pursue the same end goal of decentralizing Tc-99m supply away from aging nuclear reactors, addressing the same customer base of radiopharmacies and hospitals.

TypeDirect peer
Description

SHINE pursues commercial-scale Mo-99 production using fusion neutron technology, also targeting the same reactor-independent Tc-99m supply opportunity. Both companies compete for radiopharmacy and hospital customers seeking non-reactor isotope supply.

TypeEmerging player
Description

PETNET is a large North American radiopharmacy network operating Siemens cyclotrons to produce PET tracers including Ga-68. It is both a potential customer of ARTMS QIS for distributed production and a peer in radiopharmacy services.

TypeBroad incumbent
Description

Bracco is a large diagnostic imaging company offering contrast agents and radiopharmaceuticals. Like Lantheus, Bracco is both a potential customer for ARTMS-produced isotopes and a peer in the broader diagnostic imaging supply chain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ARTMS

Medical Isotope Production Equipmentartms.ca

ARTMS (now Telix ARTMS) develops the QUANTM Irradiation System and solid targets that enable decentralized cyclotron-based production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64), serving hospital cyclotron operators, radiopharmacies, and radiopharmaceutical manufacturers globally.

What ARTMS does

ARTMS Inc. (Alternative Radioisotope Technologies for Medical Science) is a Canadian medical technology company that develops the QUANTM Irradiation System (QIS) and a portfolio of proprietary solid targets to enable decentralized, cyclotron-based production of medical radioisotopes. Founded in 2013 by TRIUMF scientists to address projected technetium-99m supply disruptions, ARTMS targets hospital-based medical cyclotron operators, commercial nuclear pharmacies, and radiopharmaceutical manufacturers across North America, Europe, and select Asia-Pacific and Latin America markets. Following its April 2024 acquisition by Telix Pharmaceuticals Limited (ASX: TLX), ARTMS operates as Telix ARTMS, Inc. and functions as the manufacturing and supply-chain backbone for Telix's cyclotron-produced isotope strategy.

The QUANTM platform comprises three integrated components: an automatic 2-way pneumatic transfer system, a compact solid target station, and single-use enriched metal targets (QUANTM-68 Zn-68 for Ga-68, QUANTM-99 Mo-100 for Tc-99m, QUANTM-89 Y-89 for Zr-89, QUANTM-64 Ni-64 for Cu-64). Production volumes significantly exceed conventional generators — 5,000 mCi Ga-68 per 2-hour run, up to 37-40 Ci Tc-99m per 6-hour run, over 50 mCi/hour Zr-89, and over 200 mCi/hour Cu-64 — while avoiding enriched uranium and long-lived radioactive waste. The QIS is compatible with most OEM medical cyclotron platforms and is retrofittable to installed units with minimal operational disruption.

ARTMS operates a hybrid revenue model: one-time QIS hardware sales and installation services combined with recurring consumable target revenue (single-use targets plus proprietary Ni-64 recycling), augmented by regulatory licensing where radiopharmaceutical innovators reference ARTMS's FDA Drug Master Files and Health Canada Type 1 Master Files in their drug applications — most notably Telix's Gozellix (Ga-68 gozetotide), approved by FDA in 2025. Distribution combines direct enterprise sales with an OEM-embedded channel through GE Healthcare's PETtrace 800 series. ARTMS holds global patent rights for cyclotron Tc-99m production, has achieved Health Canada approval, CE marking, and FDA DMF filings, and is ISO 9001 certified.

ARTMS firmographics

Firmographics
Name
ARTMS
Legal name
ARTMS Inc.
Website
https://artms.ca
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
11–50 employees
Short description
ARTMS (now Telix ARTMS) develops the QUANTM Irradiation System and solid targets that enable decentralized cyclotron-based production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64), serving hospital cyclotron operators, radiopharmacies, and radiopharmaceutical manufacturers globally.
Ownership category
akta.pro rank

ARTMS industry classification

Industry
Product category
Medical Isotope Production Equipment
NAICS
Irradiation Apparatus Manufacturing (334517), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAG
Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Cyclotron isotope production
  • Medical radioisotope manufacturing
  • Solid target irradiation
  • Radiopharmaceutical supply
  • Diagnostic imaging isotopes

Where ARTMS is headquartered

Location

Headquarters

HQ city
Burnaby
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

ARTMS business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. QUANTM Irradiation System (QIS) Hardware Sales: Sale of QIS hardware systems (pneumatic transfer, target station, processing equipment) to cyclotron operators including hospitals, radiopharmacies, and pharmaceutical distributors. Installation and commissioning services included. System is retrofittable to existing cyclotrons with minimal disruption.
  2. QUANTM Solid Target Consumables: Recurring sale of proprietary solid target consumables (Mo-100, Zn-68, Y-89, Ni-64 targets) to cyclotron operators. Targets are single-use. ARTMS also provides proprietary recycling of Ni-64 targets for reuse, ensuring supply chain continuity.
  3. Regulatory/DMF Filing Services: ARTMS prepares and files Drug Master Files (DMF) with regulatory bodies (FDA, Health Canada) for cyclotron-produced isotopes, enabling pharmaceutical companies to reference these in their drug applications. This creates a service/embedded relationship with radiopharmaceutical innovators.
  4. Technology Integration and Licensing to OEM Partners: Licensing of QIS technology to OEM cyclotron manufacturers (e.g., GE Healthcare) for integration into their platforms. Revenue from equipment manufacturers embedding ARTMS technology in cyclotron offerings.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

ARTMS product offering

Product offering

Core offering

ARTMS develops and sells the QUANTM Irradiation System (QIS), a cyclotron-based hardware platform consisting of automatic pneumatic transfer, a compact solid target station, and processing solutions for decentralized production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64). The company also produces and supplies proprietary single-use solid targets (QUANTM-68, QUANTM-99, QUANTM-89, QUANTM-64) that pair with the QIS on hospital-based medical cyclotrons. It files Drug Master Files (DMFs) with regulators that radiopharmaceutical innovators reference in their drug applications.

Product overview

ARTMS offers the QUANTM Irradiation System (QIS) as its core platform for decentralized medical isotope production, paired with a portfolio of specialized solid targets (QUANTM-68, QUANTM-99, QUANTM-89, QUANTM-64) for producing Gallium-68, Technetium-99m, Zirconium-89, and Copper-64 respectively. The QIS enables hospitals and radiopharmacies with medical cyclotrons to produce these critical diagnostic isotopes locally, eliminating dependence on centralized reactor-based supply. The system integrates with OEM cyclotron platforms and includes automated target processing and purification capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • QUANTM Irradiation System (QIS™): Complete cyclotron-based isotope production system designed to support high efficiency, large-scale and cost-effective production of medical isotopes including Zr-89, Ga-68, Tc-99m, and Cu-64.
  • QUANTM-64 (Copper-64)
  • QUANTM-99 (Technetium-99m)
  • QUANTM-68 (Gallium-68)
  • QUANTM-89 (Zirconium-89)

Products and services

  • QUANTM Irradiation System (QIS) Complete cyclotron-based isotope production system consisting of automatic 2-way pneumatic transfer, a compact solid target station, and complete solid target processing solutions. Enables decentralized, large-scale, cost-effective production of medical isotopes on hospital-based medical cyclotrons and commercial nuclear pharmacies.
  • QUANTM-68 (Gallium-68) Solid Target Single-use Zinc-68 target with silver backing for cyclotron production of Gallium-68. Provides up to 5,000 mCi of Ga-68 per two-hour cyclotron irradiation at optimal energy of 12.7 MeV; dissolution and purification in 40 minutes. Used for PET imaging of neuroendocrine tumors and prostate cancer.
  • QUANTM-99 (Technetium-99m) Solid Target Single-use Molybdenum-100 target with copper or tantalum backing for cyclotron production of Technetium-99m. Yields up to 37-40 Ci at optimal 24 MeV and 500 uA over a 6-hour irradiation; dissolution and purification in approximately 2 hours. Approved by Health Canada for clinical use.
  • QUANTM-89 (Zirconium-89) Solid Target Single-use Yttrium-89 target with tantalum backing for cyclotron production of Zirconium-89. Yields over 50 mCi per hour at optimal 13 MeV; irradiations can exceed 12 hours; dissolution and purification under 1.5 hours. Used for Immuno-PET imaging in oncology.
  • QUANTM-64 (Copper-64) Solid Target Nickel-64 target with rhodium backing and range of Ni-64 mass for cyclotron production of Copper-64. Yields over 200 mCi per one-hour irradiation at optimal energy under 13 MeV; dissolution and purification under 2 hours. Includes proprietary Ni-64 recycling solution for stable supply. Used for oncology PET applications.

Quantifiable outcome

  • 99mTc is used in over 50 million diagnostic studies annually worldwide
  • +5 more outcomes

Companies that use ARTMS

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

ARTMS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature7 records

ARTMS partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and major.

  • POINT BiopharmacoreStrategic or Co-development Partner · 14 October 2021Tri-party co-operation with POINT Biopharma and CanProbe for the development and clinical use of innovative Ga-68-based radiopharmaceuticals in Canada. ARTMS' solid target approach enables 100-fold increase in Ga-68 availability over generator supply. POINT aims to use this supply for next-generation radiopharmaceutical therapies.
  • CanProbe (Centre for Probe Development and Commercialization and University Health Network)coreStrategic or Co-development Partner · 14 October 2021Tri-party co-operation with CanProbe (joint venture between CPDC and UHN) and POINT Biopharma for Ga-68 radiopharmaceutical development in Canada. CanProbe enables 100-fold increase in Ga-68 availability using ARTMS QIS compared to generator supply, working with innovators to meet patient needs.
  • Isotopia Molecular ImagingmajorStrategic or Co-development Partner · 19 January 2021Successful multi-curie radiolabeling of Isotopia's PSMA-11 prostate cancer imaging kit with over 2 Ci of cyclotron-produced Ga-68 using ARTMS QIS. Demonstrated 6-hour stability and radiochemical purity meeting regulatory standards. Enables near unlimited access to diagnostic product for radiopharmacies.
  • TRIUMF, BC Cancer, Centre for Probe Development and Commercialization, Lawson Health ResearchcoreStrategic or Co-development Partner · 19 May 2020Founding technology collaboration institutions. ARTMS' core technology stems from TRIUMF (Canada's particle accelerator centre), BC Cancer, CPDC, and Lawson Health Research. Early stage research funded by NSERC and the Isotope Technology Acceleration Program (ITAP). These institutions participated in Canadian consortium for Health Canada submission.
  • Telix Pharmaceuticals LimitedcoreStrategic or Co-development Partner · 6 May 2020Manufacturing collaboration for high-activity Ga-68 production using ARTMS QIS for Telix's prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11). ARTMS provides cyclotron technology and Zn-68 target irradiations; Telix provides radiochemistry expertise. Collaboration used in marketing authorization applications. ARTMS subsequently acquired by Telix in April 2024.
  • ImaginAbmajorStrategic or Co-development Partner · 1 January 2020Strategic partnership to explore novel radiochemistry manufacture of ImaginAb's lead asset 89Zr CD8 immunoPET agent. ARTMS' QIS platform produces Zr-89 for labeling of molecular targeting ligands such as antibodies for Immuno-PET imaging.
  • Odense University Hospital and University of Southern DenmarkmajorStrategic or Co-development Partner · 10 October 2019Collaboration with scientists and clinical researchers from Odense University Hospital and University of Southern Denmark. Demonstrated record Ga-68 production levels from a single short-duration irradiation of QUANTM 68Zn Target Plates. Data presented at European Association of Nuclear Medicine conference.
  • GE HealthcarecoreStrategic or Co-development Partner · 29 August 2017Strategic partnership for ARTMS' QUANTM99 Irradiation System (QIS) integrated with GE's PETtrace 800 series medical cyclotron platform. Includes agreement for first European QIS installation and joint research into expanding isotope production (Cu-64, Ga-68). ARTMS supplies equipment, technologies, and research; GE Healthcare provides platform access and distribution.
  • Alliance MedicalcoreStrategic or Co-development Partner · 15 May 2017Strategic partnership to demonstrate and gain regulatory marketing approval for alternative non-reactor Tc-99m supply within the United Kingdom. ARTMS provides hardware, know-how, and proprietary consumables to enable and demonstrate cyclotron-produced Tc-99m. Reduces UK reliance on foreign reactor-based production and enriched uranium.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

ARTMS competitors and assessment

Company assessment

Direct peers

  • IBA Radiopharma Solutions: IBA is a major manufacturer of medical cyclotrons (similar to GE Healthcare's PETtrace), providing both the cyclotron hardware and increasingly integrated targetry and processing solutions. IBA competes directly with ARTMS on integrated isotope production platforms.
  • NorthStar Medical Radioisotopes: NorthStar is the most direct competitor to ARTMS in non-reactor Mo-99/Tc-99m production, using electron accelerators rather than cyclotrons. Both companies pursue the same end goal of decentralizing Tc-99m supply away from aging nuclear reactors, addressing the same customer base of radiopharmacies and hospitals.
  • SHINE Medical Technologies: SHINE pursues commercial-scale Mo-99 production using fusion neutron technology, also targeting the same reactor-independent Tc-99m supply opportunity. Both companies compete for radiopharmacy and hospital customers seeking non-reactor isotope supply.

Broad incumbents

  • Lantheus Holdings: Lantheus is a major radiopharmaceutical company with established diagnostic imaging products (e.g., PYLARIFY PSMA-PET, Definity). Both companies serve the same end customers in nuclear medicine; ARTMS provides upstream isotope production infrastructure while Lantheus provides finished imaging agents.
  • Telix Pharmaceuticals: Telix is ARTMS's parent company post-April 2024 acquisition. As both a strategic acquirer/parent and a leading radiopharmaceutical innovator (Gozellix, Illuccix), Telix represents the vertical integration of ARTMS's isotope supply into commercial drug products.
  • Curium Pharma: Curium is one of the largest global manufacturers of diagnostic radiopharmaceuticals and SPECT/PET tracers. As both a potential customer of ARTMS isotope production technology and a competitor in the broader radiopharma supply chain, Curium is a critical industry peer.
  • Bracco Imaging: Bracco is a large diagnostic imaging company offering contrast agents and radiopharmaceuticals. Like Lantheus, Bracco is both a potential customer for ARTMS-produced isotopes and a peer in the broader diagnostic imaging supply chain.

Regional players

  • Cardinal Health Nuclear Pharmacy Services: Cardinal Health operates one of the largest US nuclear pharmacy networks, distributing radiopharmaceuticals to hospitals and clinics. It is a primary US distribution channel for SPECT/PET tracers and a potential large-scale customer of ARTMS QIS installations.

Emerging players

  • ITM Isotope Technologies Munich: ITM is a specialized radiotherapeutics company developing Lu-177 and other therapeutic isotopes, with manufacturing capabilities including cyclotron-based production. It overlaps with ARTMS in isotope production technology for emerging therapeutic applications including potential Ac-225 supply.
  • PETNET Solutions (Siemens Healthineers): PETNET is a large North American radiopharmacy network operating Siemens cyclotrons to produce PET tracers including Ga-68. It is both a potential customer of ARTMS QIS for distributed production and a peer in radiopharmacy services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ARTMS social profiles

Digital presence

ARTMS compliance and trust

Trust signal

Compliance3 records

ARTMS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ARTMS leadership team

Management profile

Number of profiles

Profiles10 records

ARTMS funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ARTMS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARTMS

What does ARTMS do?

ARTMS develops and sells the QUANTM Irradiation System (QIS), a cyclotron-based hardware platform consisting of automatic pneumatic transfer, a compact solid target station, and processing solutions for decentralized production of medical isotopes (Tc-99m, Ga-68, Zr-89, Cu-64). The company also produces and supplies proprietary single-use solid targets (QUANTM-68, QUANTM-99, QUANTM-89, QUANTM-64) that pair with the QIS on hospital-based medical cyclotrons. It files Drug Master Files (DMFs) with regulators that radiopharmaceutical innovators reference in their drug applications.

Is ARTMS a public or private company?

ARTMS is a private company. It is classified as corporate owned and is currently acquired.

When was ARTMS founded?

ARTMS was founded in 2013. It employs 11 to 50 people.

Where is ARTMS based?

ARTMS is headquartered in Burnaby, Canada, in the North America region.

How does ARTMS make money?

Four revenue lines are on record. QUANTM Irradiation System (QIS) Hardware Sales are the primary driver. The others are QUANTM Solid Target Consumables, regulatory/DMF Filing Services and technology Integration and Licensing to OEM Partners.

Who are ARTMS's main competitors?

Direct peers on record are IBA Radiopharma Solutions, NorthStar Medical Radioisotopes and SHINE Medical Technologies. Broad incumbents are Lantheus Holdings, Telix Pharmaceuticals, Curium Pharma and Bracco Imaging. Cardinal Health Nuclear Pharmacy Services is listed as a regional player. Emerging players are ITM Isotope Technologies Munich and PETNET Solutions (Siemens Healthineers).

Does ARTMS have an API?

No public API is recorded for ARTMS.

What industry is ARTMS in?

ARTMS's product category is Medical Isotope Production Equipment. Its primary akta.pro industry code is EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.), with a secondary code of EUAKAIAE, Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain). Its NAICS code is 334517 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AdvfnIBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®IBA announced an agreement with ARTMS (a Telix company) to distribute the QIS solid-target cyclotron technology to cyclotron users worldwide. QIS is referenced in FDA filings for multiple approved products and enables production of gallium-68 and zirconium-89. The partnership aims to accelerate availability of diagnostic and therapeutic isotopes for theranostics.BioSpaceIBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®IBA announced an agreement with ARTMS (a Telix company) to distribute the QUANTM Irradiation System (QIS) solid-target cyclotron technology to cyclotron users worldwide. QIS is validated for gallium-68 and zirconium-89 production, with ARTMS serving existing customers directly. The partnership aims to expand theranostics access through scalable production infrastructure.Nate[Photo] Kiss of Life Bell, 'Lovely Eye Contact': Nate EntertainmentOn August 12, Kiss of Life Bell danced while waiting for the 1st place announcement during the MBC every1 and MBC M 'Show Champion' live broadcast. The show featured multiple artists, including ARTMS, EMOTI:M, and others.NateKiss of Life aims for the top spot [Photoen HD]: Nate EntertainmentThe article reports on the live performance event of MBC's 'Show Champion' held on August 12 at the MBC Dream Center in Ilsan, featuring various artists. Among the attendees were KISS OF LIFE, along with other groups such as ARTMS and EMOTI:M, highlighting a competitive atmosphere for ranking. This event underscores the active participation of these groups in the entertainment industry.openPR.comDiagnostic Radioisotopes Market Overview: Major Segments, Strategic Developments, and Leading CompaniesThe diagnostic radioisotopes market is projected to reach $9.26 billion by 2030, growing at a compound annual growth rate of 8.5%, driven by increasing demand for oncology imaging, cardiac nuclear diagnostics, and an aging global population. In April 2024, Telix Pharmaceuticals Limited, an Australian biotechnology firm, acquired the Canadian company ARTMS to strengthen its supply chain and manufacturing capabilities in cyclotron-based isotope production. Key growth drivers include broader adoption of PET and SPECT imaging technologies, innovation in short half-life isotopes, and enhanced radiopharmaceutical supply chains.openPR.comGrowth Patterns, Segment Analysis, and Competitive Strategies Influencing the Technetium-99m MarketThe technetium-99m market is projected to reach $6.01 billion by 2030 with a compound annual growth rate of 4.8%, driven by rising demand for precision diagnostic imaging and innovations in radiopharmaceuticals. In April 2024, Australian biopharmaceutical company Telix Pharmaceuticals Limited acquired Canada-based ARTMS Inc. to strengthen its supply chain management of medical isotopes including technetium-99m through cyclotron-based production technology. In June 2024, UK-based Serac Healthcare Limited received Fast Track Designation from the US FDA for its novel imaging agent 99mTc-maraciclatide, designed for SPECT-CT diagnosis of superficial peritoneal endometriosis.GlobeNewswireTelix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.IBA (Ion Beam Applications S.A.) has signed a contract with Telix Pharmaceuticals Limited for the initial order of four Cyclone KIUBE cyclotrons to be installed at RLS Radiopharmacies sites in the United States, supporting Telix's strategic expansion of its U.S. manufacturing footprint for producing diagnostic and therapeutic isotopes and radiopharmaceuticals for cancer care. The agreement reinforces IBA's leading position in radiopharmaceutical production solutions while enabling Telix to manufacture critical radio-metals including Gallium-68, Zirconium-89, Technetium-99m, and Copper-64 in-house at cGMP-compliant facilities, reducing reliance on external suppliers. Each cyclotron will be equipped with ARTMS's QUANTM Irradiation System, a subsidiary of Telix, representing a key technical milestone for localized, high-yield isotope production.AETOSWireTelix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.Telix Pharmaceuticals completed its acquisition of ARTMS, enhancing its supply chain and manufacturing control over medical isotopes. ARTMS will support production of isotopes like zirconium-89, gallium-68, technetium-99m, and copper-64, and its cyclotron technologies can produce alpha-emitting isotopes such as actinium-225 and astatine-211.TelixpharmaTelix to Acquire ARTMS, Inc. and its Advanced Isotope Production PlatformTelix Pharmaceuticals has entered into an agreement to acquire ARTMS, Inc., a Canadian firm specializing in cyclotron-based radioisotope production technology and its associated manufacturing assets. The acquisition aims to vertically integrate Telix's supply chain, enhance the production reliability of key diagnostic isotopes like 68Ga and 89Zr for products such as Illuccix® and Zircaix®, and support the development of therapeutic radionuclides. This move is expected to improve gross margins and provide greater control over the manufacturing of commercially important medical isotopes.GlobeNewswireTelix to Acquire ARTMS, Inc. and its Advanced Isotope Production PlatformTelix Pharmaceuticals agreed to acquire ARTMS Inc., a cyclotron-based isotope production firm, for US$42.5 million upfront plus earn-outs. The deal aims to enhance Telix's supply chain control for diagnostic isotopes like 89Zr and 68Ga, with plans to produce therapeutic actinium-225 in-house by end-2024.